KMT2E [The Human Chemical-Genetic Interaction Map Project]

This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong.
======= KMT2E =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: KMT2E
  * **<color #00a2e8>Official Name</color>**: lysine methyltransferase 2E
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=55904|55904]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/Q8IZD2|Q8IZD2]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=KMT2E&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20KMT2E|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/608444|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**:  This gene is a member of the myeloid/lymphoid or mixed-lineage leukemia (MLL) family and encodes a protein with an N-terminal PHD zinc finger and a central SET domain. Overexpression of the protein inhibits cell cycle progression. Alternate transcriptional splice variants have been characterized. [provided by RefSeq, Jul 2008]. 
  * **<color #00a2e8>UniProt Summary</color>**: N/A

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|SET|
|PHD|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|positive regulation of histone H3-K4 trimethylation|
|regulation of histone H3-K4 trimethylation|
|positive regulation of histone H3-K4 methylation|
|histone-lysine N-methyltransferase activity|
|transcriptionally active chromatin|
|regulation of histone H3-K4 methylation|
|positive regulation of G1/S transition of mitotic cell cycle|
|positive regulation of histone methylation|
|positive regulation of cell cycle G1/S phase transition|
|DNA alkylation|
|DNA methylation|
|regulation of megakaryocyte differentiation|
|methylated histone binding|
|regulation of histone methylation|
|DNA methylation or demethylation|
|histone lysine methylation|
|positive regulation of mitotic cell cycle phase transition|
|erythrocyte differentiation|
|peptidyl-lysine methylation|
|DNA modification|
|erythrocyte homeostasis|
|positive regulation of histone modification|
|histone methylation|
|positive regulation of cell cycle phase transition|
|positive regulation of chromatin organization|
|myeloid cell homeostasis|
|chromatin|
|protein methylation|
|protein alkylation|
|regulation of histone modification|
|cell cycle arrest|
|regulation of G1/S transition of mitotic cell cycle|
|positive regulation of mitotic cell cycle|
|microtubule organizing center|
|regulation of cell cycle G1/S phase transition|
|positive regulation of chromosome organization|
|regulation of chromatin organization|
|homeostasis of number of cells|
|myeloid cell differentiation|
|regulation of myeloid cell differentiation|
|macromolecule methylation|
|positive regulation of cell cycle process|
|methylation|
|peptidyl-lysine modification|
|enzyme binding|
|regulation of chromosome organization|
|histone modification|
|covalent chromatin modification|
|positive regulation of cell cycle|
|nuclear speck|
|regulation of mitotic cell cycle phase transition|
|regulation of cell cycle phase transition|
|regulation of hemopoiesis|
|neutrophil mediated immunity|
|neutrophil activation|
|granulocyte activation|
|myeloid leukocyte mediated immunity|
|hemopoiesis|
|negative regulation of cell cycle|
|myeloid leukocyte activation|
|protein-containing complex|
|hematopoietic or lymphoid organ development|
|positive regulation of organelle organization|
|regulation of mitotic cell cycle|
|immune system development|
|chromatin organization|
|DNA metabolic process|
|regulation of cell cycle process|
|leukocyte mediated immunity|
|peptidyl-amino acid modification|
|leukocyte activation|
|cell cycle process|
|chromosome organization|
|cell activation|
|immune effector process|
|regulation of cell cycle|
|positive regulation of cellular component organization|
|positive regulation of protein modification process|
|regulation of organelle organization|
|cell cycle|
|positive regulation of transcription, DNA-templated|
|positive regulation of cellular protein metabolic process|
|positive regulation of nucleic acid-templated transcription|
|positive regulation of RNA biosynthetic process|
|homeostatic process|
|regulation of immune system process|
|positive regulation of protein metabolic process|
|positive regulation of RNA metabolic process|
|regulation of cell differentiation|
|regulation of protein modification process|
|positive regulation of nucleobase-containing compound metabolic process|
|positive regulation of macromolecule biosynthetic process|
|positive regulation of cellular biosynthetic process|
|positive regulation of gene expression|
|positive regulation of biosynthetic process|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp290|LLY-283 2.6μM R06 exp290]]|-2.88|
|[[:results:exp499|LY2090314 0.003μM R08 exp499]]|-2.48|
|[[:results:exp539|42°C R08 exp539]]|-2.3|
|[[:results:exp299|Talazoparib 0.006μM R06 exp299]]|-1.96|
|[[:results:exp500|LY2090314 0.003μM R08 exp500 no dilution day6]]|-1.94|
|[[:results:exp175|3-Bromopyruvate 7μM R04 exp175]]|-1.87|
|[[:results:exp2|5-Fluorouracil 20μM R00 exp2]]|-1.73|
|[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|-1.71|
|[[:results:exp264|Arsenate 40μM R06 exp264]]|-1.71|
|[[:results:exp256|HMS-I1 10μM R06 exp256]]|-1.7|
|[[:results:exp321|ABT-702 5μM plus Deferoxamine 11μM R07 exp321]]|1.75|
|[[:results:exp461|BS-181 20μM R08 exp461]]|1.75|
|[[:results:exp145|PNU96415E 10μM R03 exp145]]|1.76|
|[[:results:exp468|CB-5083 0.4μM R08 exp468]]|1.8|
|[[:results:exp497|Lead acetate 2000μM R08 exp497]]|1.83|
|[[:results:exp399|Salubrinal 20μM R07 exp399]]|1.91|
|[[:results:exp71|KU-0063794 3.8μM R02 exp71]]|1.94|
|[[:results:exp349|Cytochalasin-B 5μM R07 exp349]]|2.09|
|[[:results:exp417|Tubastatin-A 2.5μM R07 exp417]]|2.13|
|[[:results:exp29|Rapamycin 1μM R00 exp29]]|3.59|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:a:ankrd11|ANKRD11]]|0.495|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 7982
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 7.51 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='KMT2E Expression in NALM6 Cells: 7.51'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>